ZHANG Jian, WU Min, ZHANG Zi-sen, et al. Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 189-192.
ZHANG Jian, WU Min, ZHANG Zi-sen, et al. Influence of Yangzheng Xiaoji Capsule Cellular Immune Function and Angiogenesis in Treating Primary Liver Cancer after Arterial Chemoembolization[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(13): 189-192. DOI: 10.13422/j.cnki.syfjx.2014130189.
Objective: Discuss the influence and mechanism of action of Yangzheng Xiaoji capsule to patients' progression free survival(PFS) in treating primary liver cancer after arterial chemoembolization. Method: Ninety-seven patients were randomly divided into control group (47 cases) and observation group (50 cases)by random number table.Patients in the control group received Fufang Banmao capsules
3 grains/time
2 times/day.Patients in the observation group received Yangzheng Xiaoji capsule
4 grains/time
2 times/day.Treatment was ending when progression of ill appeared.Progression free survival was recorded.Before treatment and at the third mouth after treatment
KPS was graded and level of T lymphocyte subpopulation of peripheral blood and natural killer cell(NK) were detected.vascular endothelial growth factor(VEGF)
fibroblast growth factor(FGF) and alpha fetal protein (AFP) were also detected. Result: PFS in control group were(17.5±6.2) weeks which were(21.3±6.9)weeks in observation group
which meat PFS in observation group was longer than in control group(P<0.01). Treatment 3 months after the control group T lymphocyte subsets (CD3+
CD4+
CD8+
CD4+/CD8+) and NK in control group changed indistinctively.But CD3+
CD4+
CD4+/CD8+and NK in observation group increased(P<0.01)
and which in observation group were higher than those in control group(P<0.01)
CD8+in observation group was lower than in control group(P<0.01).After 3 mouths of treatment
compared with the time before treatment
level of serous VEGF
bFGF and AFP decreased(P<0.01)
which in observation group were lower than those in control group(P<0.01). Conclusion: Yangzheng Xiaoji capsule can prolong patients' progression free survival in treating primary liver cancer after arterial chemoembolization
it stabilized patients' quality of lives
and its improving patients' cellular immune function and restraining angiogenesis.